IP Library Granted Patent US 10,301,689
Granted Patent B1
US 10,301,689 · App. 15/664,807 · Granted May 28, 2019

Methods and compositions for detection of Zika viral infections

Inventors: Chandan Shee (Newark, CA); Jerzy Majka (Foster City, CA); Bernardo Araujo (Mountain View, CA); Ushati Das Chakravarty (Mountain View, CA); Katrina Sullivan-Bibee (Palo Alto, CA); Jerald Sapida (San Leandro, CA); Kristine Salazar (Fremont, CA)
Assignee: Theranos IP Company, LLC
C12Q1/701
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,301,689
App. No.
15/664,807
Granted
May 28, 2019
Kind
B1
Abstract

Applicant discloses herein kits for identifying the presence of Zika virus in a sample. In embodiments, these kits comprise reagents disclosed herein. Applicant further provides kits for use in detecting ZIKV in a sample, the kits comprising reagents disclosed herein. In embodiments, kits include primers directed to Zika virus (ZIKV) nucleic acid sequences, the primers capable of hybridizing to ZIKV nucleic acids and to copies of ZIKV nucleic acids (including to cDNA copies of ZIKV nucleic acids). Applicant discloses herein reagents for detecting Zika virus (ZIKV) in a sample, the reagents including one or more nucleic acid primers that are capable of hybridizing to a ZIKV nucleic acid (including to cDNA copies of ZIKV nucleic acids).

Claims (20)

1. A kit for identifying the presence of ZIKA virus in a sample, comprising a nucleic acid primer comprising a nucleic acid sequence selected from the group SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, and a buffer.

2. The kit of claim 1 , wherein the nucleic acid primer comprises a nucleic acid sequence selected from the group SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.

3. A kit for identifying the presence of ZIKA virus in a sample, comprising a nucleic acid primer comprising a variant of a nucleic acid sequence selected from the group SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, and a buffer, wherein the variant has at least about 95% sequence identity to the nucleic acid sequence.

4. The kit of claim 3 , wherein the nucleic acid primer comprises a nucleic acid primer comprising a variant of a nucleic acid sequence selected from the group SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, and a buffer, wherein the variant has at least about 95% sequence identity to the nucleic acid sequence.

5. The kit of claim 1 , wherein the buffer is selected from phosphate, tris(hydroxymethyl)aminomethane (TRIS), 3-(N-morpholino) propanesulfonic acid (MOPS), 3-morpholino-2-hydroxypropanesulfonic acid (MOPSO), 2-(N-morpholino)ethanesulfonic acid (IVIES), N-(2-Acetamido)-iminodiacetic acid (ADA), and piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES).

6. The kit of claim 2 , wherein the buffer is tris(hydroxymethyl)aminomethane (TRIS).

7. The kit of claim 1 , further comprising a reporter molecule.

8. The kit of claim 2 , further comprising a reporter molecule.

9. The kit of claim 3 , further comprising a reporter molecule.

10. The kit of claim 4 , further comprising a reporter molecule.

11. The kit of claim 1 , wherein the nucleic acid primer comprises a reporter molecule.

12. The kit of claim 2 , wherein the nucleic acid primer comprises a reporter molecule.

13. The kit of claim 3 , wherein the nucleic acid primer comprises a reporter molecule.

14. The kit of claim 4 , wherein the nucleic acid primer comprises a reporter molecule.

15. The kit of claim 11 , wherein the reporter molecule comprises a fluorescent moiety, and the nucleic acid primer further comprises a quenching moiety effective to quench fluorescence from the fluorescent moiety when the primer is not hybridized to a target nucleic acid sequence.

16. The kit of claim 12 , wherein the reporter molecule comprises a fluorescent moiety, and the nucleic acid primer further comprises a quenching moiety effective to quench fluorescence from the fluorescent moiety when the primer is not hybridized to a target nucleic acid sequence.

17. The kit of claim 13 , wherein the reporter molecule comprises a fluorescent moiety, and the nucleic acid primer further comprises a quenching moiety effective to quench fluorescence from the fluorescent moiety when the primer is not hybridized to a target nucleic acid sequence.

18. The kit of claim 14 , wherein the reporter molecule comprises a fluorescent moiety, and the nucleic acid primer further comprises a quenching moiety effective to quench fluorescence from the fluorescent moiety when the primer is not hybridized to a target nucleic acid sequence.

19. A kit for identifying the presence of ZIKA virus in a sample, comprising a nucleic acid primer comprising a variant of a nucleic acid sequence selected from the group SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, and a buffer, wherein the variant has at least about 90% sequence identity to the nucleic acid sequence.

20. The kit of claim 19 , further comprising a reporter molecule, wherein the reporter molecule comprises a fluorescent moiety, and the nucleic acid primer further comprises a quenching moiety effective to quench fluorescence from the fluorescent moiety when the primer is not hybridized to a target nucleic acid sequence.

Assignments (5)
CHANGE OF NAME Recorded Apr 3, 2020
From: THERANOS IP COMPANY, LLC
To: LABRADOR DIAGNOSTICS LLC
Reel/Frame 052313/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2019
From: SHEE, CHANDAN; MAJKA, JERZY; ARAUJO, BERNARDO; CHAKRAVARTY, USHATI DAS; SULLIVAN-BIBEE, KATRINA; SAPIDA, JERALD; SALAZAR, KRISTINE
To: THERANOS, INC.
Reel/Frame 050131/0412 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2018
From: THERANOS, INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 045205/0686 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2017
From: THERANOS INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 044838/0909 →
SECURITY INTEREST Recorded Dec 12, 2017
From: THERANOS IP COMPANY, LLC
To: FORTRESS CREDIT CORP.
Reel/Frame 044839/0568 →
Continuity (5)
Provisional Application 62369179 · Jul 31, 2016
Provisional Application 62369009 · Jul 29, 2016
Provisional Application 62368961 · Jul 29, 2016
Provisional Application 62368995 · Jul 29, 2016
Provisional Application 62369006 · Jul 29, 2016